title: [Evaluation of the effect of ilaprazole on intragastric pH in patients with duodenal ulcer].
abstract: OBJECTIVE
  To evaluate the effect of ilaprazole enteric tablets on intragastric pH in duodenal ulcer patients.
  
  
  METHODS
  A randomized, double blind, positive controlled clinical trial was carried out. A total of forty-two patients with duodenal ulcer were randomized into low dose ilaprazole group (5 mg/d), medium dose ilaprazole group (10 mg/d), high dose ilaprazole group (20 mg/d) and omeprazole group (20 mg/d). An ambulatory 24 hour intragastric pH study was performed at the fifth treatment day. Fraction time pH above 3, 4 or 5, median values of 24 hour diurnal pH and 12 hour nocturnal pH, the percentage of patients with total time pH above 3, 4 or 5 at least for 18 hours were evaluated.
  
  
  RESULTS
  There were no significant differences of fraction time pH above 3 or 4, median values of 24 hour diurnal pH and 12 hour nocturnal pH and the percentage of patients with total time pH above 3, 4 or 5 at least for 18 hours among all the groups with different doses of ilaprazole and the omeprazole group. The fraction time pH above 5 in medium and high dose ilaprazole groups were (87.96 + or - 12.29)% and (89.86 + or - 15.18)% respectively, which was higher than that in low dose ilaprazole group [(67.17 + or - 30.16)%] and omeprazole group [(76.14 + or - 16.75)%], P < 0.05.
  
  
  CONCLUSIONS
  Ilaprazole has a strong effect on intragastric acid control with a dose dependent trend.
authors.affiliation: Department of Gastroenterology, the Third Hospital, Peking University, Beijing 100191, China. liyazhou@medmail.com.cn
authors.forename: Li-ya
authors.initials: LY
authors.lastname: Zhou
authors.forename: San-ren
authors.initials: SR
authors.lastname: Lin
authors.forename: Yun-sheng
authors.initials: YS
authors.lastname: Yang
authors.forename: Shu-tian
authors.initials: ST
authors.lastname: Zhang
authors.forename: Yao-zong
authors.initials: YZ
authors.lastname: Yuan
authors.forename: Rui-hua
authors.initials: RH
authors.lastname: Shi
authors.forename: Xiao-hua
authors.initials: XH
authors.lastname: Hou
authors.forename: Jie-lai
authors.initials: JL
authors.lastname: Xia
authors.forename: Hai-tang
authors.initials: HT
authors.lastname: Hu
authors.forename: Xiang-hong
authors.initials: XH
authors.lastname: Qin
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D013270:Stomach / Q000503:physiopathology*; D013454:Sulfoxides / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; C119615:ilaprazole; D009853:Omeprazole